Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection

E-resources

PDF

Full text

Peer reviewed Open access

Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection

STONE DOGGETT, J; OJO, Kayode K; FAN, Erkang; MALY, Dustin J; VAN VOORHIS, Wesley C

Antimicrobial agents and chemotherapy, 06/2014, Volume: 58, Issue: 6

Journal Article

Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

Keep searching

Author

STONE DOGGETT, J | OJO, Kayode K | FAN, Erkang | MALY, Dustin J | VAN VOORHIS, Wesley C

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme